| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3297702 | Gastroenterology | 2010 | 17 Pages |
Abstract
In the first year of treatment for CHB, tenofovir and entecavir are the most potent oral antiviral agents for HBeAg-positive patients; tenofovir is most effective for HBeAg-negative patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Gloria Woo, George Tomlinson, Yasunori Nishikawa, Matthew Kowgier, Morris Sherman, David K.H. Wong, Ba Pham, Wendy J. Ungar, Thomas R. Einarson, E. Jenny Heathcote, Murray Krahn,